Oxford BioMedica is announcing that its Innurex programme for nerve regeneration in spinal cord injury has been awarded $150,000 from the Christopher Reeve Paralysis Foundation
At the time of the Annual General Meeting on the 20th April 2004 Oxford BioMedica released an update statement which said that "the company is announcing that its Innurex programme for nerve regeneration in spinal cord injury has been awarded $150,000 from the Christopher Reeve Paralysis Foundation".
The company wishes to make it clear that the Christopher Reeve Paralysis Foundation has awarded the grant to Kings College London to explore the use of Innurex in spinal cord injury.
This study, at King's College, is being conducted in collaboration with Oxford BioMedica and the company retains all commercial rights.
